Drug Profile
VX 850
Alternative Names: VX-850Latest Information Update: 27 Jun 2007
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Inflammation
Most Recent Events
- 05 Feb 2004 This compound is still in active development
- 28 Sep 2001 The development schedule for VX 850 has been accelerated
- 31 Dec 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)